Trial Profile
An open-label study to evaluate the inflammatory markers in adult patients with asthma associated with allergic rhinitis receiving montelukast therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Biomarker; Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 01 Feb 2007 Status changed from recruiting.
- 12 Dec 2006 New trial record.